EMPA
Clinical data
ATC code
  • none
Identifiers
  • N-Ethyl-N2-(6-methoxy-3-pyridinyl)-N2-[(2-methylphenyl)sulfonyl]-N-(3-pyridinylmethyl)glycinamide
CAS Number
PubChem CID
ChemSpider
UNII
ECHA InfoCard100.233.393 Edit this at Wikidata
Chemical and physical data
FormulaC23H26N4O4S
Molar mass454.55 g·mol−1
3D model (JSmol)
  • CCN(CC1=CN=CC=C1)C(=O)CN(C2=CN=C(C=C2)OC)S(=O)(=O)C3=CC=CC=C3C
  • InChI=1S/C23H26N4O4S/c1-4-26(16-19-9-7-13-24-14-19)23(28)17-27(20-11-12-22(31-3)25-15-20)32(29,30)21-10-6-5-8-18(21)2/h5-15H,4,16-17H2,1-3H3
  • Key:KJPHTXTWFHVJIG-UHFFFAOYSA-N

EMPA is a selective antagonist of the OX2 receptor, with 900-fold selectivity in binding for OX2 over OX1.[1][2]

See also

References

  1. ^ Malherbe P, Borroni E, Pinard E, Wettstein JG, Knoflach F (September 2009). "Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison with selective OX1 and OX2 antagonists". Molecular Pharmacology. 76 (3): 618–31. doi:10.1124/mol.109.055152. PMID 19542319. S2CID 5702143.
  2. ^ Malherbe P, Borroni E, Gobbi L, Knust H, Nettekoven M, Pinard E, et al. (April 2009). "Biochemical and behavioural characterization of EMPA, a novel high-affinity, selective antagonist for the OX(2) receptor". British Journal of Pharmacology. 156 (8): 1326–41. doi:10.1111/j.1476-5381.2009.00127.x. PMC 2697736. PMID 19751316.